Sign in

    Jenny KimBTIG

    Jenny Kim is currently an Investor and Operator with a diverse professional background, having held titles such as Partner in Fund Operations at Two Bear Capital and Senior Director of Science and Policy Engagement at Juul Labs. Her expertise spans fund operations, strategic finance, and corporate strategy, with past roles also including Director of Corporate Strategy at Juul Labs and strategic investment positions at Hyundai Ventures and Horsley Bridge Partners. Kim began her investment career as an Investment Analyst at Sequoia Capital and previously contributed to oncology research at Harvard Medical School and Massachusetts General Hospital. She holds degrees from Harvard University and the University of California, Berkeley, demonstrating a strong academic foundation alongside her professional growth, though detailed metrics on her investment performance, covered companies, securities licenses, or FINRA registration are not publicly available.

    Jenny Kim's questions to INmune Bio Inc (INMB) leadership

    Jenny Kim's questions to INmune Bio Inc (INMB) leadership • Q2 2025

    Question

    Jenny Kim of BTIG asked about potential refinements to the EMAC endpoint measurement and the registrational precedent for the NPI behavioral marker in FDA discussions.

    Answer

    VP of Neuroscience, CJ Barnum, explained that the EMAC performed as expected, capturing cognitive change in the high-inflammation patient subgroup. He expressed confidence that the FDA would have a favorable opinion of EMAC, noting its use by several other companies and upcoming publications, which helps build scientific consensus. The question regarding the NPI was not fully addressed due to audio issues.

    Ask Fintool Equity Research AI